Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
05. März 2014 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated...
Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201
05. Dezember 2013 12:49 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pilot bioequivalence study in...